Is Ra Medical Systems a Reliable Penny Stock to Get?

The shares of commercial-stage medical tool manufacturer Ra Medical Systems (RMED) have actually rolled 92.7% in cost over the past year as a result of capitalist issues bordering the business’s bad economic wellness. Additionally, given the unpredictability surrounding the FDA’s approval of its DABRA catheter laser system, the concern comes to be, is the penny stock a safe bet currently? Read on, let’s learn.

Medical tool firm Ra Medical Systems, Inc. (RMED – Get Ranking) in Carlsbad, Calif., is styles, establishes, and also markets excimer lasers to deal with vascular conditions. The company has made significant progression in vital campaigns, including its DABRA innovation laser system and also atherectomy critical clinical research. Nevertheless, the RMED stock quote has declined 86.8% in cost over the past six months and also 92.7% over the past year, mirroring financier issues over its disappointing income and also revenues growth as well as the sale of its dermatology service.

Closing the other day’s session at $0.42, the stock is currently trading 95.7% below its 52-week high of $9.82, showing bearish belief.

While the commercial-stage medical device firm has submitted a 510( k) application with the U.S. Food and Drug Administration (FDA) for its DABRA catheter, its commercialization leads remain uncertain until its product gets authorization from the FDA. In addition, the stock’s negative profitability might make investors nervous.

Selling Shares

Last month, RMED valued an underwritten public offering of systems of its common stock, consisting of warrants to acquire as much as 27.6 million shares of the ordinary shares and also pre-funded warrants to acquire approximately 14.47 shares of common stock. The medical tool maker anticipates about $12.1 million in gross proceeds from the offering.

Divestiture of Dermatology Business

Top 10 Stocks for 2022
In the third quarter, RMED completed the sale of its Pharos dermatology service for web proceeds of approximately $3.5 million. This was done as a part of the business’s plans to concentrate its resources on the marketplace for medical gadgets to treat outer artery illness (PAD). Nonetheless, the divestiture could adversely influence the medical gadget maker’s profits as well as cost framework in the near term and cause RMED’s stock cost to roll even more.

Bleak Productivity

The business’s trailing-12-month ROA and also cash from operations are negative 100.6% and $31.33 million, respectively. In addition, its trailing-12-month gross profit margin, ROE and ROTC are adverse 18.9%, 115%, and 67%, respectively. And also its 0.12% possession turn over ratio is 65.2% less than the 0.34% market average.

Faltering Financials
RMED’s net income from continuing operations came in at $5,000 for the 3rd quarter, finished Sept. 30, 2021, versus $68,000 in the third quarter of 2020. Its gross loss stood at $24,000 for the quarter, while operating loss can be found in at $7.39 million. Furthermore, its net loss totaled up to $4.3 million, while its loss per share was available in at $0.67. RMED reported an adverse adjusted EBITDA of $6.95 million versus $6.06 million in the prior-year quarter. As well as its overall business expenses expanded 2.1% year-over-year to $7.15 million throughout this duration.

POWR Ratings Show Bleak Leads

RMED has a total D ranking, which translates to Sell in our POWR Scores system. The POWR Scores are determined by taking into consideration 118 distinct variables, with each element heavy to an optimum level.

Our proprietary ranking system also reviews each stock based on eight distinctive categories. RMED has an F quality for High quality. This reflects the stock’s unfavorable ROA as well as cash flow from procedures.

The business has a D grade in Energy, consistent with its rate decline over the past six months. Additionally, it has an F quality for Stability, which remains in sync with its reasonably high beta of 1.65.

Past the qualities I have actually highlighted, one can have a look at extra RMED rankings for View, Development, as well as Worth here. Amongst the 166 stocks in the D-rated Medical– Devices & Equipment sector, RMED is rated # 119.


Analysts anticipate RMED’s EPS to remain adverse this year. While its efforts to develop DABRA catheters bode well, its unfavorable profit margin as well as insufficient monetary stamina might create its shares to decrease further. Furthermore, the uncertainty surrounding the regulatory clearance as well as commercialization of its DABRA laser system can raise financiers’ issues. So, we assume it is best stayed clear of currently.

How Does Ra Medical Systems (RMED) Compare To its Peers?

While RMED has a total D (Market) ranking in our proprietary score system, one could want to think about having a look at its market peers, Fonar Corporation (FONR – Get Score), Electromed, Inc. (ELMD – Obtain Rating), and also Abbott Laboratories (ABT – Get Ranking), having an A (Strong Buy) ranking.

Comments are closed.